Design, Synthesis, and Multivariate Quantitative Structure−Activity Relationship of SalicylanilidesPotent Inhibitors of Type III Secretion in <i>Yersinia</i>
作者:Markus K. Dahlgren、Anna M. Kauppi、Ing-Marie Olsson、Anna Linusson、Mikael Elofsson
DOI:10.1021/jm070741b
日期:2007.11.1
possible structural variation. A basic structure-activity relationship was established and then used to cherry-pick compounds from a principal component analysis score plot of salicylanilides to generate a second set. A third set with increased likelihood of biological activity was designed using D-optimal onion design. A quantitative structure-activity relationship model using hierarchical partial least-square
PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES
申请人:Semple J. Edward
公开号:US20120108592A1
公开(公告)日:2012-05-03
A new class of salicylanilides is described. These compounds show strong activity against hepatitis viruses.
描述了一类新的水杨酰苯胺类化合物。这些化合物对肝炎病毒表现出强大的活性。
Synthesis and Antifungal Activity of 2-(4-Chlorophenylcarbamoyl)phenyl Acetate
作者:Xiaorong Tang、Hui Feng、Quan Du、Ling Wang
DOI:10.14233/ajchem.2013.14536
日期:——
2-(4-Chlorophenylcarbamoyl)phenyl acetate was synthesized by the ammonolysis of 2-(chlorocarbonyl)phenyl acetate. Its structure was confirmed by IR and 1H NMR. Its antifungal activity against Sclerotinia sclerotiorum and Helminthosprium maydis has been determined in the laboratory. Results showed that it had good antifungal activity against the above two different pathogenic fungi of plants. Its median effective concentrations (EC50) were 28 mg L-1 and 2.3 mg L-1, respectively.
This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.